ANIP - ANI Pharmaceuticals, Inc.
| Previous Close | 69.00 |
| Open | 69.09 |
| Bid | 66.95 x 800 |
| Ask | 72.00 x 1800 |
| Day's Range | 68.24 - 70.75 |
| 52 Week Range | 36.92 - 72.81 |
| Volume | 104,098 |
| Avg. Volume | 80,638 |
| Market Cap | 818.15M |
| Beta (3Y Monthly) | 1.95 |
| PE Ratio (TTM) | 52.98 |
| EPS (TTM) | 1.30 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.67 |
- Zacks•2 days ago
ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.
- Zacks•3 days ago
Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
- Zacks•4 days ago
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.
- Zacks•5 days ago
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Is (ANIP) Outperforming Other Medical Stocks This Year?
- Zacks•5 days ago
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
- PR Newswire•5 days ago
ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product
BAUDETTE, Minn., April 15, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (ANIP) today announced that it has entered into a Distribution Agreement with a U.S. based injectable manufacturer to commercialize a unique specialty injectable product. Key terms of the 10-year Agreement include cumulative milestones of up to $2M, payable by ANI. Upon launch, ANI will receive a 50% share of net profits generated from product revenues. The product will be commercialized in the ANI label.
- Zacks•8 days ago
ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.
- Zacks•8 days ago
5 Stocks With Increasing Cash Flows to Scoop Up Big Gains
Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.
- Zacks•9 days ago
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
- Zacks•9 days ago
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
- Zacks•10 days ago
Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin
Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.
- Zacks•11 days ago
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.
- Zacks•11 days ago
Coherus (CHRS) Catches Eye: Stock Jumps 6.9%
Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Zacks•12 days ago
Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Zacks•15 days ago
Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher
Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.
- Zacks•15 days ago
The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire
The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire
- Zacks•16 days ago
Fears of Far-Reaching Economic Slowdown Diminish: 5 Picks
Encouraging service sector figures from Europe and China, along with increasing optimism in U.S.-China trade negotiations ease fears of a global economic downturn.
- Zacks•16 days ago
5 Stocks With Recent Price Strength Despite Market Volatility
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
- Zacks•19 days ago
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
- Zacks•19 days ago
Moving Average Crossover Alert: ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. (ANIP) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks•22 days ago
4 Small Biotech Stocks Likely to Witness More Upside in 2019
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
- Zacks•23 days ago
All You Need to Know About ANI (ANIP) Rating Upgrade to Strong Buy
ANI (ANIP) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
